Intervacc AB - Thread - From Horse Vaccine to Veterinary Pharmaceutical Company

Interesting calculation. You would be willing to pay 1,500–2,000 MSEK for a company that has one product generating revenue with a present value of 400 MSEK? :sweat_smile:

The reason for today’s share price crash is likely Erik Penser, who halved their target price from a ridiculous level of 92–102 SEK to 48–54. Sales forecasts and margins fell drastically in their analysis, and cash flow positivity will be reached in 2025 at the earliest.

In my opinion, there is still more hot air in the stock than real future cash flow.

1 Like